Home

Lacutamab, a Phase-3 ready asset: replay of the October 28 event

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca

IPH4502, our Antibody Drug Conjugate targeting Nectin-4

Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma

Collaborating with a strong network to advance our pipeline